Getinge AB Stock Forecast for 2023 - 2025 - 2030
Updated on 04/27/2024
Getinge AB Stock Forecast and Price Target
Given the average yearlong price target of kr228.00 provided by three prominent analysts over the past few months, there is a potential downside of approximately -3.02% from the last closing price in April, 2024 for Getinge AB's stock if it is reached. This estimation is based on a high estimate of kr300.00 and a low estimate of kr186.00. If you're interested in GETI B stock, it's important to compare it to other companies in the industry.
-3.02% Downside
Getinge AB Fair Value Forecast for 2023 - 2025 - 2030
In the last four years, Getinge AB's Price has seen a drop from kr306.20 to kr0.00 – a 100.00% decrease. For next year, analysts predict Fair Value of kr228.75, which would mean an increase of 100.00%. Over the next seven years, experts predict that Getinge AB's Fair Value will grow at a rate of 100.00%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| JNJ Stock Forecast | Johnson & Johnson | Outperform |
9
|
$146.14 | Buy/Sell | $174.55 | 16.33% |
| TMO Stock Forecast | Thermo Fisher Scientific | Outperform |
10
|
$573.60 | Buy/Sell | $591.94 | 7.22% |
| ROG Stock Forecast | Roche Holding | Hold |
16
|
CHF221.00 | Buy/Sell | CHF307.83 | 23.30% |
| ABT Stock Forecast | Abbott Laboratories | Outperform |
9
|
$107.53 | Buy/Sell | $118.92 | 17.64% |
| DHR Stock Forecast | Danaher | Outperform |
10
|
$246.58 | Buy/Sell | $260.33 | 9.50% |
Getinge AB Revenue Forecast for 2023 - 2025 - 2030
In the last three years, Getinge AB's Revenue has grown by 6.73%, rising from kr29.82B to kr31.83B. For next year, analysts predict Revenue of kr33.21B, which would mean an increase of 4.34%. Over the next seven years, experts predict that Getinge AB's Revenue will grow at a rate of 42.32%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| GE Stock Forecast | General Electric | Outperform |
8
|
$162.35 | Buy/Sell | $144.00 | 10.87% |
| SYK Stock Forecast | Stryker Corp | Outperform |
10
|
$335.61 | Buy/Sell | $353.16 | 9.20% |
| BSX Stock Forecast | Boston Scientific | Outperform |
11
|
$73.17 | Buy/Sell | $70.14 | 12.07% |
.jpg)
Getinge AB Dividend per Share Forecast for 2023 - 2025 - 2030
In the last three years, Getinge AB's Dividend per Share has grown, rising from kr3.00 to kr4.40 – a growth of 46.67%. In the next year, analysts believe that Dividend per Share will reach kr4.63 – an increase of 5.23%. For the next seven years, the forecast is for Dividend per Share to grow by 26.83%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| MDT Stock Forecast | Medtronic | Outperform |
11
|
$79.74 | Buy/Sell | $92.47 | 19.76% |
| 6501 Stock Forecast | Hitachi | Outperform |
4
|
¥13.48k | Buy/Sell | ¥11.29k | 5.38% |
| BDX Stock Forecast | Becton Dickinson and Co | Outperform |
9
|
$231.55 | Buy/Sell | $284.47 | 19.84% |
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| ECL Stock Forecast | Ecolab | Hold |
18
|
$221.10 | Buy/Sell | $205.36 | 4.48% |
| EW Stock Forecast | Edwards Lifesciences Corp | Outperform |
11
|
$86.43 | Buy/Sell | $91.18 | 12.23% |
| RMD Stock Forecast | ResMed Inc | Outperform |
17
|
$218.06 | Buy/Sell | $201.32 | 0.43% |
Getinge AB EBITDA Forecast for 2023 - 2025 - 2030
In the last three years, Getinge AB's EBITDA has decreased from kr6.42B to kr4.74B – a 26.13% drop. In the next year, analysts believe that EBITDA will reach kr6.64B – an increase of 40.04%. For the next seven years, the forecast is for EBITDA to grow by 57.19%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| CERN Stock Forecast | Cerner | - |
13
|
$94.92 | Buy/Sell | $95.00 | -63.34% |
| FTV Stock Forecast | Fortive | Outperform |
18
|
$75.97 | Buy/Sell | $86.47 | 15.84% |
| WST Stock Forecast | West Pharmaceutical Services | Outperform |
18
|
$360.43 | Buy/Sell | $380.80 | 6.82% |
Getinge AB EBIT Forecast for 2023 - 2025 - 2030
In the last three years, Getinge AB's EBIT has decreased by 28.74%, going from kr5.19B to kr3.70B. For the next year, analysts predict that EBIT will reach kr4.48B – an increase of 21.04%. Over the next seven years, experts believe that Getinge AB's EBIT will grow at a rate of 34.71%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| SIEMENS Stock Forecast | Siemens | Outperform |
16
|
Rp5.75k | Buy/Sell | Rp4.02k | -15.51% |
| 4543 Stock Forecast | Terumo | Outperform |
18
|
¥5.63k | Buy/Sell | ¥4.97k | -9.46% |
| BAX Stock Forecast | Baxter International Inc | Outperform |
17
|
$40.13 | Buy/Sell | $44.86 | 12.14% |
Getinge AB EPS Price Prediction Forecast for 2023 - 2025 - 2030
In the last four years, Getinge AB's EPS has seen a drop from kr14.43 to kr0.00 – a 100.00% decrease. For next year, analysts predict EPS of kr10.78, which would mean an increase of 100.00%. Over the next seven years, experts predict that Getinge AB's EPS will grow at a rate of 100.00%.
| Ticker | Name | Consensus | Stock Rating | Price | Buy/Sell | Price Target | Upside/Downside |
|---|---|---|---|---|---|---|---|
| STE Stock Forecast | STERIS | Outperform |
13
|
$203.90 | Buy/Sell | $238.33 | 18.20% |
| COO Stock Forecast | The Cooper Companies | Outperform |
13
|
$88.84 | Buy/Sell | $391.40 | 23.82% |
| SRT3 Stock Forecast | Sartorius | Outperform |
18
|
290.20€ | Buy/Sell | 281.57€ | 15.44% |
.jpg)